

Prophylactic **TRE**atment **O**f the du**C**tus **A**rteriosus in **P**reterm infants by **A**cetaminophen

Dear Investigators, dear National Hubs,

We are pleased to announce that we have included our first patients in the Treocapa study at Nantes University Hospital, first site open for patients recruitment. Indeed, **3 patients have been included**: 2 patients in Phase II and 1 patient in Phase III.

By the end of November 2020, 10 sites will be open for recruitment: 5 sites in France, 4 sites in Finland and 1 site in Switzerland. In addition, at least 8 additional site initiations visits will be performed by the end of year in France, Finland, Estonia and Portugal.



TREOCAPA study was registered on clinicaltrials.gov in July 2020.
Check out NCT04459117.



ONGOING TRAININGS

- ✓ Trainings of *Clinical Project Managers and Clinical Research Associates* on monitoring activities have continued throughout September and October 2020.
- ✓ Trainings of *National Hub PV referents* on Pharmacovigilance activities have been performed on October 8, 2020

More news!

The European Foundation for the Care of Newborn Infants (EFCNI) is the first pan-European organisation and network to represent the interests of preterm and newborn infants and their families. EFCNI will ensure public and patient involvement (PPI) during all phases of the TREOCAPA clinical trial. We want to make sure that the parents of preterm babies have a say, are informed and reassured throughout the

whole process since, in the end, the results will have a direct effect on their lives and those of their children. We will keep you updated here about the steps we are taking to ensure that the patient/parent voice is heard throughout the trial.



TREOCAPA are proud supporters of World Prematurity Day 2020.

Your TREOCAPA team

TREOCAPA is a study co-developed with parents and their European representatives.



This study is funded by the c4c project. Find out more here: <https://conect4children.org/>